krt8 Antibody

What is KRT8 and why is it significant in biological research?

KRT8 (Keratin 8) is a type II cytoskeletal protein that belongs to the basic subfamily of high molecular weight cytokeratins. It typically exists in combination with Keratin 18 (KRT18) and is primarily expressed in non-squamous epithelia, including glandular epithelium in tissues such as thyroid, breast, gastrointestinal tract, respiratory tract, and urogenital tract . KRT8 has gained significant attention in research due to its aberrant expression in multiple cancer types and its potential as a diagnostic and prognostic biomarker .

How do I select the appropriate KRT8 antibody for my research?

Selection should be based on:

• Target specificity: Determine whether you need antibodies that recognize only KRT8 or those that recognize both KRT8/KRT18 complexes

• Host species: Consider compatibility with other antibodies for co-staining experiments

• Clonality: Monoclonal antibodies offer higher specificity for particular epitopes, while polyclonal antibodies may provide broader recognition

• Application compatibility: Verify validation data for your specific application (WB, IHC, IF, FCM)

• Post-translational modification recognition: Specialized antibodies exist for detecting phosphorylated forms (e.g., phospho-Ser73)

• Species reactivity: Confirm cross-reactivity with your model organism (human, mouse, rat)

What are the common applications for KRT8 antibodies in research?

KRT8 antibodies are versatile tools employed in multiple research techniques:

• Western blotting: For quantitative analysis of KRT8 expression levels

• Immunohistochemistry: For detection in tissue samples, particularly cancer diagnostics

• Immunofluorescence: For subcellular localization studies and co-localization experiments

• Flow cytometry: For quantitative analysis of cell populations expressing KRT8

• ELISA: For quantitative measurement in serum or cell extracts

What optimization steps are critical when using KRT8 antibodies for immunohistochemistry?

Successful IHC with KRT8 antibodies requires several optimization steps:

• Fixation protocol: Formalin-fixed, paraffin-embedded (FFPE) tissues work well with most KRT8 antibodies

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is typically recommended

• Antibody dilution: Titrate antibody concentrations (starting around 1 μg/ml as seen in literature)

• Incubation conditions: Optimize time (typically overnight at 4°C or 1-2 hours at room temperature)

• Detection system: Choose appropriate secondary antibody and visualization method

• Positive controls: Include tissues known to express KRT8 (e.g., colon, prostate)

• Negative controls: Include primary antibody omission and tissues known to lack KRT8 expression

How can I optimize Western blot protocols for KRT8 detection?

For optimal Western blot results:

• Sample preparation: Complete lysis of epithelial samples is crucial for releasing KRT8 (53.7 kDa protein)

• Protein loading: Start with 20-30 μg total protein per lane

• Gel percentage: 10% SDS-PAGE gels are typically suitable

• Transfer conditions: Semi-dry or wet transfer with PVDF membranes

• Blocking: 5% non-fat milk or BSA in TBST (1 hour at room temperature)

• Primary antibody: Dilute according to manufacturer recommendations (typically 1:1000)

• Controls: Include GAPDH (1:5000) or Lamin B1 (1:1000) as loading controls

• Stripping and reprobing: If detecting both phosphorylated and total KRT8, consider sequential detection with stripping between antibodies

What considerations are important when designing KRT8 knockdown experiments?

When designing KRT8 knockdown studies:

• Knockdown method: shRNA approaches have been successfully used in published studies

• Validation: Confirm knockdown efficiency by Western blot

• Off-target effects: Use multiple shRNA sequences targeting different regions of KRT8 to rule out off-target effects

• Rescue experiments: Consider including a rescue condition with shRNA-resistant KRT8 constructs

• Timing: Allow sufficient time for protein turnover after knockdown (typically 48-72 hours)

• Functional assays: Plan to assess proliferation (CCK-8, colony formation), apoptosis, migration, and invasion as these are key functions affected by KRT8

How can KRT8 antibodies be used to study epithelial-to-mesenchymal transition (EMT)?

KRT8 antibodies are valuable tools for investigating EMT:

• Dual staining approach: Co-stain with KRT8 and EMT markers (E-cadherin, N-cadherin, Vimentin, Slug)

• Time course experiments: Monitor KRT8 expression changes during EMT induction

• Quantitative assessment: Use flow cytometry with KRT8 antibodies to quantify populations undergoing EMT

• Comparative analysis: Analyze KRT8 expression alongside EMT marker expression in knockdown/overexpression models

• In vivo models: Use KRT8 immunostaining to assess EMT status in xenograft or genetically engineered mouse models

What are the critical controls needed when using KRT8 antibodies for cancer biomarker studies?

Essential controls for biomarker studies include:

• Tissue controls: Include normal adjacent tissue alongside tumor samples

• Isotype controls: Use matched isotype antibodies to control for non-specific binding

• Antibody validation: Validate antibody specificity using positive and negative cell lines

• Technical replicates: Perform technical replicates to ensure reproducibility

• Scoring system: Establish a clear and reproducible scoring system for KRT8 expression levels

• Blinded analysis: Conduct blinded scoring to prevent bias

• Correlation analysis: Correlate KRT8 expression with established clinical parameters to validate its biomarker potential

How can I investigate the relationship between KRT8 and NF-κB signaling using antibody-based techniques?

To study KRT8-NF-κB interactions:

• Co-immunoprecipitation: Use KRT8 antibodies to pull down associated proteins and probe for NF-κB pathway components

• Cellular fractionation: Analyze nuclear vs. cytoplasmic fractions using KRT8 and NF-κB antibodies

• Phosphorylation analysis: Utilize phospho-specific antibodies to monitor p-IκBα and p-p65 levels after KRT8 knockdown

• Stimulation experiments: Assess how KRT8 knockdown affects TNF-α-induced nuclear translocation of p65

• ChIP assays: Evaluate binding of NF-κB to target promoters in the context of KRT8 manipulation

• Reporter assays: Measure NF-κB-driven transcriptional activity in KRT8-manipulated cells

What approaches can I use to study KRT8 phosphorylation and its functional significance?

To investigate KRT8 phosphorylation:

• Phospho-specific antibodies: Use antibodies that specifically recognize phosphorylated Ser73 of KRT8

• Phosphatase treatment: Compare antibody reactivity before and after phosphatase treatment

• Kinase inhibitors: Test how various kinase inhibitors affect KRT8 phosphorylation status

• Phosphomimetic mutations: Create S73D (phosphomimetic) and S73A (phospho-null) mutants

• Mass spectrometry: Use immunoprecipitation with KRT8 antibodies followed by mass spectrometry to identify phosphorylation sites

• Cell-based ELISA: Quantify changes in phosphorylation levels under different conditions

What are the considerations when studying KRT8 in injury-specific progenitor cells and tissue regeneration?

When investigating KRT8 in tissue injury and regeneration:

• Single-cell resolution: Use immunofluorescence with KRT8 antibodies for high-resolution imaging of individual cells

• Lineage tracing: Combine KRT8 antibody staining with genetic lineage tracing methods

• Morphological analysis: Perform confocal microscopy with KRT8 staining to assess cell shape changes (sphericity, flattening)

• Co-expression analysis: Use multi-color immunofluorescence to detect co-expression with other markers (e.g., Sftpc in lung injury models)

• Temporal dynamics: Establish a clear timeline with multiple sampling points to capture the dynamics of KRT8 expression during injury and repair

• 3D imaging: Consider thick tissue sections (e.g., 300 micron) for comprehensive morphometric analysis

Why might I observe discrepancies between KRT8 detection at mRNA versus protein levels?

Several factors can explain discrepancies:

• Post-transcriptional regulation: microRNAs may regulate KRT8 mRNA without affecting transcription

• Protein stability: KRT8 protein may have different half-life under various conditions

• Antibody specificity: The antibody may recognize specific post-translational modifications or conformations not proportional to total protein

• Technical artifacts: Different sensitivity and dynamic range between RT-PCR and Western blot/IHC

• Sample preparation: Epithelial cells might be underrepresented in whole tissue RNA preparations

• Heterogeneity: Single-cell versus bulk analysis may reveal different patterns

How can I reconcile contradictory findings when KRT8 shows variable expression patterns across different cancer datasets?

To address contradictory findings:

• Cancer subtype analysis: Stratify analysis by molecular subtypes within the same cancer type

• Histological validation: Confirm RNA-seq or microarray data with histological assessment

• Multiple antibody approach: Use different antibody clones recognizing distinct epitopes

• Quantification method: Standardize quantification methods across different datasets

• Metadata analysis: Consider patient characteristics, treatment history, and tumor staging

• Statistical approaches: Use meta-analysis techniques to integrate data from multiple sources

• Technical validation: Validate findings using multiple technical approaches (IHC, Western blot, ELISA)

What should I consider when interpreting KRT8 immunostaining results in the context of tumor heterogeneity?

For accurate interpretation of heterogeneous tumors:

How can KRT8 antibodies be used in single-cell analysis techniques?

Applications in single-cell analysis include:

• Single-cell immunofluorescence: Combined with tissue clearing techniques for 3D visualization

• Mass cytometry (CyTOF): Metal-conjugated KRT8 antibodies for high-dimensional single-cell analysis

• Imaging mass cytometry: Spatial resolution of KRT8 expression in tissue context

• Single-cell Western blot: Quantify KRT8 protein expression in individual cells

• CODEX multiplexed imaging: Combine KRT8 with dozens of other markers for comprehensive analysis

• Integration with scRNA-seq: Validate transcriptomic findings at protein level in the same cells or serial sections

What are the considerations for studying KRT8 in patient-derived organoid models?

When using KRT8 antibodies in organoid research:

• 3D immunofluorescence: Optimize staining protocols for whole-mount organoids

• Live-cell imaging: Consider using fluorescently tagged antibody fragments for live imaging

• Quantification approaches: Develop 3D quantification methods for spatial expression patterns

• Heterogeneity assessment: Analyze variation in KRT8 expression across different organoids from the same patient

• Drug response correlation: Correlate KRT8 expression patterns with therapeutic responses

• Differentiation tracking: Use KRT8 as a marker to track epithelial differentiation states in organoid development

How can I use KRT8 antibodies to investigate the tumor microenvironment and cell-cell interactions?

To study KRT8 in the context of the tumor microenvironment:

• Multiplex immunofluorescence: Combine KRT8 with stromal, immune, and endothelial markers

• Spatial analysis: Quantify distances between KRT8+ cells and other cell types

• Cell-cell junction analysis: Co-stain with junction proteins to assess epithelial integrity

• Receptor-ligand analysis: Correlate KRT8 expression with specific receptor-ligand pairs between tumor and stromal cells

• 3D reconstruction: Create 3D maps of KRT8+ cells in relation to blood vessels and immune infiltrates

• In situ transcriptomics: Combine KRT8 protein detection with RNA markers using methods like MERFISH

Table 1: Common Applications and Recommended Controls for KRT8 Antibodies